Metraipolis › archive › dc_8f23665a6791

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41464721
DOI
10.3390/jcm14248819
License (as archived)
solo-consultazione
Archived
2026-11-07T16:25:56.809Z
SHA-256 of the archived text
ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7
Stable URL of this page
https://metraipolis.com/documento/dc_8f23665a6791

How to cite

Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721 — Europe PMC (en), https://europepmc.org/article/MED/41464721 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8f23665a6791 (Metraipolis archive dc_8f23665a6791, sha256 ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7)
BibTeX
@misc{dc8f23665a6791,
  title = {Safety and Effectiveness of Multi-Switch Between Adalimumab Originator and Biosimilars: A Multicenter (SUSTAIN) Study — Europe PMC PMID:41464721},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41464721},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8f23665a6791; sha256 ceeffaadef3f0ba3c6e73a311a1ecade286baf41a3662548579c754c337e50f7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41464721. Agents can read the archived copy with the MCP tool read_document.